Head-to-Head Trial Compares Interleukin Inhibitors for Psoriatic Arthritis
A clinical trial presented at the American College of Rheumatology conference showed that bimekizumab achieved higher rates of joint symptom improvement in psoriatic arthritis patients than risankizumab over six months.
❤️Conditions & CarePhoto: Medical Xpress
Key points
- Bimekizumab led to a 50 percent symptom improvement in 55 percent of patients at six months compared to 44 percent for risankizumab.
- The clinical trial involved 553 adults with active psoriatic arthritis and evaluated both drugs head-to-head over a six-month period.
- Candida fungal infections occurred slightly more often with bimekizumab, while overall serious adverse event rates remained low for both therapies.
A head-to-head clinical trial presented at the American College of Rheumatology conference in Orlando, Florida, suggests that the dual interleukin inhibitor bimekizumab may provide greater joint symptom relief for adults with active psoriatic arthritis than risankizumab.
The trial evaluated 553 adult participants with active psoriatic arthritis who were randomly assigned to receive regular injections of either bimekizumab or risankizumab. Researchers measured success using the ACR50 standard, which represents at least a 50 percent improvement in disease activity. At four months, 50 percent of participants receiving bimekizumab reached this benchmark compared to 38 percent of those taking risankizumab. By six months, response rates rose to 55 percent for bimekizumab and 44 percent for risankizumab.
Both biologic medications work by blocking interleukins, which are chemical messengers that drive systemic inflammation. However, bimekizumab, approved by the U.S. Food and Drug Administration in 2023, targets two interleukins, whereas risankizumab, approved in 2019, targets one. Serious side effects were documented in under 2 percent of participants taking bimekizumab and approximately 3 percent of those taking risankizumab. Candida fungal infections occurred in 3 percent of the bimekizumab group compared to 1 percent in the risankizumab group due to the drugs' immune-dampening mechanisms.
What to know: While comparative clinical trials offer helpful data on drug performance, treatment efficacy and side effect profiles differ among individuals. Patients living with psoriatic arthritis should consult their doctor or specialist before making any changes to their treatment plan.
Source Medical Xpress — medicalxpress.com/news/2026-11-trial-reveals-immune-dampening-drug.html ↗
Read next
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.
🧠Mind & Mental HealthThe Role of Daily Mobility Training in Managing Sedentary Tension
A two-week personal trial suggests that incorporating short, daily mobility exercises may help alleviate stiffness associated with sedentary desk work. Experts note that …
🧠Mind & Mental HealthNew Theoretical Framework Explores Memory Formation and Dementia
Researchers have proposed a new model suggesting the brain's limbic system functions similarly to generative AI, potentially offering a new way to understand and classify…